EPIVIR-HBV Drug Patent Profile

When do Epivir-hbv patents expire, and what generic alternatives are available?

Epivir-hbv is a drug marketed by Glaxosmithkline and is included in two NDAs.

The generic ingredient in EPIVIR-HBV is lamivudine. There are twenty-nine drug master file entries for this compound. Fourteen suppliers are listed for this compound. Additional details are available on the lamivudine profile page.

DrugPatentWatch^® Litigation and Generic Entry Outlook for Epivir-hbv

A generic version of EPIVIR-HBV was approved as lamivudine by APOTEX on December 2^nd, 2011.

Summary for EPIVIR-HBV

US Patents:	0
Applicants:	1
NDAs:	2
Raw Ingredient (Bulk) Api Vendors:	146
Clinical Trials:	46
Patent Applications:	4,297
Drug Prices:	Drug price information for EPIVIR-HBV
DailyMed Link:	EPIVIR-HBV at DailyMed

See drug prices for EPIVIR-HBV

Recent Clinical Trials for EPIVIR-HBV

Identify potential brand extensions & 505(b)(2) entrants

Sponsor	Phase
Roswell Park Cancer Institute	Phase 2
Bess Frost, PhD	Phase 1/Phase 2
Owens Medical Research Foundation	Phase 1/Phase 2

See all EPIVIR-HBV clinical trials

US Patents and Regulatory Information for EPIVIR-HBV

Applicant	Tradename	Generic Name	Dosage	NDA	Approval Date	TE	Type	RLD	RS	Patent No.	Patent Expiration	Product	Substance	Delist Req.	Exclusivity Expiration
Glaxosmithkline	EPIVIR-HBV	lamivudine	SOLUTION;ORAL	021004-001	Dec 8, 1998		DISCN	Yes	No
Glaxosmithkline	EPIVIR-HBV	lamivudine	TABLET;ORAL	021003-001	Dec 8, 1998		DISCN	Yes	No

EU/EMA Drug Approvals for EPIVIR-HBV

Company	Drugname	Inn	Product Number / Indication	Status	Generic	Biosimilar	Orphan	Marketing Authorisation	Marketing Refusal
Teva B.V.	Lamivudine Teva Pharma B.V.	lamivudine	EMEA/H/C/001111Lamivudine Teva Pharma B.V. is indicated as part of antiretroviral combination therapy for the treatment of human-immunodeficiency-virus (HIV)-infected adults and children.	Authorised	yes	no	no	2009-12-10
Teva B.V.	Lamivudine Teva	lamivudine	EMEA/H/C/001113Lamivudine Teva is indicated for the treatment of chronic hepatitis B in adults with:compensated liver disease with evidence of active viral replication, persistently elevated serum alanine aminotransferase (ALT) levels and histological evidence of active liver inflammation and / or fibrosis. Initiation of lamivudine treatment should only be considered when the use of an alternative antiviral agent with a higher genetic barrier is not available or appropriate (see in section 5.1).	Authorised	yes	no	no	2009-10-23
GlaxoSmithKline (Ireland) Limited	Zeffix	lamivudine	EMEA/H/C/000242Zeffix is indicated for the treatment of chronic hepatitis B in adults with:, , , compensated liver disease with evidence of active viral replication, persistently elevated serum alanine aminotransferase (ALT) levels and histological evidence of active liver inflammation and / or fibrosis. Initiation of lamivudine treatment should only be considered when the use of an alternative antiviral agent with a higher genetic barrier is not available or appropriate;, decompensated liver disease in combination with a second agent without cross-resistance to lamivudine., ,	Authorised	no	no	no	1999-07-29

International Patents for EPIVIR-HBV

See the table below for patents covering EPIVIR-HBV around the world.

Country	Patent Number	Title	Estimated Expiration
African Regional IP Organization (ARIPO)	136	Substituted:- 1,3-oxathiolanes with antiviral properties.
African Regional IP Organization (ARIPO)	9000163
Austria	129247

Supplementary Protection Certificates for EPIVIR-HBV

Patent Number	Supplementary Protection Certificate	SPC Country	SPC Expiration	SPC Description
0382526	SPC/GB96/043	United Kingdom		PRODUCT NAME: LAMIVUDINE, OPTIONALLY IN THE FORM OF A PHARMACEUTICALLY ACCEPTABLE SALT; REGISTERED: CH 53662 19960228; CH 53663 19960228; UK EU/1/96/015/001 19960808; UK EU/1/96/015/002 19960808
0382526	96C0035	Belgium		PRODUCT NAME: LAMIVUDINE; NAT. REGISTRATION NO/DATE: EU/1/96/015/001 19960808; FIRST REGISTRATION: CH 53 662 013 19960228
0382526	C960025	Netherlands		PRODUCT NAME: LAMIVUDINUM, DESGEWENST IN DE VORM VAN EEN FARMACEUTISCH AAN- VAARDBAAR ZOUT; REGISTRATION NO/DATE: EU/1/96/015/001 - EU/1/96/015/002 19960808

EPIVIR-HBV Market Dynamics and Financial Trajectory: Exclusivity, Pricing, Revenue Drivers, and Generic Risk

Last updated: July 30, 2026

EPIVIR-HBV is the brand name of lamivudine (oral antiviral) for hepatitis B virus (HBV). The financial trajectory has followed a classic mature-NDA-to-generic path: dominant early share in HBV, later erosion as multiple generic lamivudine products entered, and pricing pressure as payers shifted to low-cost equivalents. Current market dynamics are driven less by clinical differentiation and more by (1) formulary access, (2) substitutability by other HBV nucleos(t)ide analogs, and (3) tablet-level supply and contracting economics.

Market outcome in practice: EPIVIR-HBV is a low-growth, low-margin, largely generic-driven segment of the HBV market rather than a long-duration proprietary revenue engine.

---

What is EPIVIR-HBV (lamivudine) and what drives its HBV prescribing today?

Featured snippet answer: EPIVIR-HBV is a lamivudine-based oral therapy for chronic HBV. Its use is now constrained by widespread availability of generics and clinical preference for higher-barrier antivirals in many guidelines.

How is EPIVIR-HBV positioned clinically?

Lamivudine is a nucleoside reverse transcriptase inhibitor (NRTI) used for HBV viral suppression. Its commercial vulnerability stems from well-documented virologic limitations over time, including emergence of resistance during long treatment courses.

Practical impact on market dynamics

• Resistance risk in chronic, long-duration therapy reduces clinician inclination where newer agents are available.
• Generic economics compress brand pricing power.
• Formulary protocols often favor other HBV agents (tenofovir disoproxil fumarate, tenofovir alafenamide, entecavir depending on payer and patient profile).

Which HBV patient segments still use lamivudine?

Lamivudine typically persists where:

• Cost containment dictates use of lowest acquisition cost antivirals.
• Switching risk is managed carefully in patients stable on lamivudine.
• Treatment choice is constrained by payer coverage rules or intolerance/suitability for alternatives.

How does EPIVIR-HBV compare with competing HBV antivirals that shape market share?

EPIVIR-HBV competes indirectly through line-item formulary decisions against:

• Tenofovir-based regimens
• Entecavir
• Other nucleos(t)ide analogs in specific clinical pathways

The practical commercial result is that EPIVIR-HBV participates in a highly substitutable market where differentiation is limited once generics are available.

---

How has EPIVIR-HBV revenue and financial trajectory changed from brand launch to maturity?

Featured snippet answer: EPIVIR-HBV’s financial trajectory follows a declining-to-flat curve driven by generic entry and substitution by higher-barrier HBV therapies.

Revenue trajectory pattern in mature HBV nucleos(t)ide markets

For older HBV antivirals like lamivudine, the typical financial shape is:

1. Strong early-to-mid adoption as the brand establishes HBV monotherapy/combination use.
2. Gradual erosion from generics as patents and exclusivities end.
3. Further share loss as prescribers shift to newer, higher-barrier antivirals.
4. Stabilization at lower value due to formulary contracting for low-cost therapy.

Key financial drivers that determine whether EPIVIR-HBV holds value

• Wholesale acquisition cost (WAC) vs. net price: net price falls after contracting pressure.
• Payer rebate intensity: increases as competition intensifies and volume shifts to preferred generics.
• Channel mix: store-and-mail order pharmacy vs. specialty distribution is usually less relevant for lamivudine than for more specialized agents, but contracting still matters.
• Inventory and SKU rationalization: once generic dominance occurs, brand-level distinct SKUs lose.

Commercial ceiling after generic penetration

After generic lamivudine becomes the procurement baseline, the brand’s revenue is typically limited to:

• Remaining patients who have not switched
• Prescriber preference in constrained settings
• Contract exceptions that keep a brand listed temporarily

---

What market dynamics impact EPIVIR-HBV net price, volume, and payer contracting?

Featured snippet answer: EPIVIR-HBV dynamics are dominated by generic competition, formulary tiering, and substitution toward higher-barrier HBV therapies.

Formulary access and switching protocols

Payers reduce spending by:

• Placing antivirals on preferred tiers only for specific acquisition-cost thresholds
• Using prior authorization and step edits for non-preferred agents
• Encouraging switch when clinically appropriate

For a low-differentiation drug like lamivudine, switching pressure is structurally high once equivalent low-cost products are available.

Acquisition-cost compression

Even if a brand product remains listed, net price tends to track the lowest-cost equivalent. That creates a ceiling on monetization that is mostly independent of manufacturing or marketing.

Competition does not require direct claims

EPIVIR-HBV faces indirect competitive pressure because clinicians compare therapeutic durability and long-term resistance profiles. Newer agents reduce the need for lamivudine in many chronic-treatment pathways.

---

Does EPIVIR-HBV face exclusivity or patent barriers that affect generics?

Featured snippet answer: Market access is shaped primarily by generic lamivudine availability. Any remaining brand exclusivity would be expected to have already expired for an older HBV therapy; current competition is therefore mostly generic-driven.

What patents typically mattered for lamivudine brands

For older HBV brands built around well-known APIs, the patent estate usually focused on:

• Specific formulations or dosing strengths
• Use claims tied to HBV
• Process or polymorph claims in some cases

In a mature product, these barriers either expire long before now or are outweighed by the generic API’s ability to use established production and formulation know-how.

Orange Book and FDA listing status

Because EPIVIR-HBV is a legacy lamivudine HBV brand, market reality generally reflects:

• Extensive generic listing coverage
• Limited ability for brand differentiation once patents end

(For a live Orange Book snapshot and exact list of patents, the analysis depends on current FDA database fields and the brand’s specific NDA listing identifiers. The required FDA listing data is not provided in the prompt.)

---

What generic entry risks exist for EPIVIR-HBV today?

Featured snippet answer: The main generic risk is already realized. The current risk profile is less about new generic entries and more about further price erosion from ongoing generic competition and biosystem-wide contracting.

How generic competition continues even after first entry

Even after initial generic launch, ongoing dynamics include:

• Additional generic suppliers entering low-cost status
• Pharmacy benefit manager (PBM) re-optimization of preferred products
• Contract-based consolidation that pushes net pricing downward

What could still shift the economics

Economics can change with:

• Sudden new supplier availability
• Large contract wins by a dominant generic manufacturer
• Supply disruptions that briefly raise market prices, followed by rapid normalization

---

How does EPIVIR-HBV compare with tenofovir and entecavir in market outcomes?

Featured snippet answer: Tenofovir and entecavir generally capture more durable share because they have stronger resistance profiles for long-term HBV suppression, pushing lamivudine into lower-acquisition-cost and switch-maintenance niches.

Commercial substitution logic

Payers and clinicians tend to align around:

• Resistance durability
• Total cost of care (including downstream antiviral changes)
• Long-term patient retention on effective regimens

This structural advantage typically translates into higher share for newer agents, even where lamivudine remains cheapest at the point of purchase.

---

What litigation and settlement dynamics matter for EPIVIR-HBV?

Featured snippet answer: For older lamivudine brands, the major litigation that shapes later generic entry typically occurred around the time the brand’s primary exclusivities ended. Current EPIVIR-HBV economics are usually not the product of active litigation, but of established generic competition.

How to interpret “no active litigation” in commercial terms

Even without ongoing Paragraph IV activity:

• Net prices decline from competitive pressure
• Formularies shift toward preferred generics
• Brand value remains capped by substitution incentives

(Active case lists and specific settlement terms cannot be produced from the prompt because no case identifiers or jurisdictions are included.)

---

Where does EPIVIR-HBV sell: geography, channel mix, and procurement structure?

Featured snippet answer: EPIVIR-HBV sales are primarily US-driven under FDA-regulated channels, with channel economics determined by PBMs, wholesaler contracting, and retail mail distribution for tablet-based NRTIs.

US procurement mechanics

• Pharmacy and mail-order contracting determines the effective market price.
• PBM formularies determine patient assignment and refill economics.
• Generic lamivudine availability limits brand share regardless of detail-level marketing.

International dynamics

Outside the US, similar dynamics apply:

• Generic access accelerates
• National treatment guidelines affect selection across agents
• Tender-based procurement can create periodic supply-cost swings

But geographic financials require specific company segment reporting, which is not provided in the prompt.

---

What manufacturing and supply factors affect EPIVIR-HBV availability and pricing?

Featured snippet answer: In generics-heavy HBV lamivudine markets, pricing is most sensitive to supplier concentration and contract-based procurement rather than patented manufacturing methods.

Common supply-shock effects in generics

• Plant-level disruptions can temporarily reduce supply and lift net pricing.
• When supply stabilizes, prices typically revert quickly under PBM contracting.

What matters for continuity of supply

• Dose strength stability
• Regulatory batch release timeliness
• Ongoing quality system compliance

These factors can influence which supplier becomes the preferred contractor but do not typically expand total market size.

---

Key takeaways

• EPIVIR-HBV’s financial trajectory is shaped by mature-drug dynamics: generic competition compresses net pricing and caps brand revenues.
• Share declines are reinforced by clinical substitution toward higher-barrier HBV agents, pushing lamivudine into cost-driven and stability-maintenance niches.
• Current market outcomes are governed by formulary tiering, rebate contracting, and supplier economics, not by incremental product innovation.
• Generic entry risk is structurally already realized; the ongoing risk is continued price erosion and supplier-driven procurement changes rather than first-wave generic launches.

---

FAQs

1) Why do payers prefer newer HBV antivirals over lamivudine even when lamivudine is cheaper?
Because resistance durability and downstream treatment switching can lower total cost of care and improve long-term viral suppression outcomes in payer models.

2) Does EPIVIR-HBV still face meaningful patent exclusivity protection?
For a legacy lamivudine HBV brand, exclusivity effects are generally minimal in today’s pricing because generic coverage is already established; exclusivity questions depend on current Orange Book patent lists for the specific NDA.

3) What drives EPIVIR-HBV net price more: wholesale acquisition cost or PBM rebate mechanics?
PBM contracting and rebate mechanics dominate net price in mature generic markets; WAC is typically not the binding constraint once generics are preferred.

4) How quickly does pricing normalize after lamivudine supply disruptions?
Typically quickly after supply restoration because PBMs and distributors can shift to alternative suppliers and reinstate preferred contracting economics.

5) What is the main commercial risk for manufacturers of lamivudine products?
Loss of preferred formulary status to lower acquisition cost competitors and contract re-bids that compress net margins.

---

References (APA)

1. FDA. (n.d.). Orange Book: Approved Drug Products with Therapeutic Equivalence Evaluations. U.S. Food and Drug Administration.
2. World Health Organization. (n.d.). Guidelines for the management of hepatitis B infection. World Health Organization.
3. AASLD/IDSA/other guideline bodies. (n.d.). Chronic hepatitis B treatment guidance. (Guideline document set accessed via respective organizations’ publications.)